Quoin Pharmaceuticals, Ltd.: Business Overview, Financials & Competitive Analysis
Quoin Pharmaceuticals, Ltd. scores 8/10 on the AskCyborg Cyborg Score (Strong). Late-stage rare disease play with multiple regulatory tailwinds and pivotal trial data catalysts anticipated within 12 months. Compelling catalysts with near-term pivotal trial data expected in H2 2026 and regulatory approvals potential as early as late 2026/early 2027. Strong cash position following ~$105M financing and clear path to commercialization.
What is Quoin Pharmaceuticals, Ltd.'s industry? Quoin Pharmaceuticals, Ltd. (quoinpharma.com) operates in Specialty Pharmaceuticals - Rare and Orphan Diseases. AskCyborg classifies Quoin Pharmaceuticals, Ltd. under Specialty Pharmaceuticals - Rare and Orphan Diseases in its company registry.
Quoin Pharmaceuticals is a late-stage specialty pharmaceutical company developing treatments for rare and orphan diseases, with primary focus on severe genetic skin disorders. The company's lead asset, QRX003, is a to...
Cyborg Score thesis
Late-stage rare disease play with multiple regulatory tailwinds and pivotal trial data catalysts anticipated within 12...
Read the full analyst-debate transcript →Get the Latest Quoin Pharmaceuticals, Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeQuoin Pharmaceuticals, Ltd. Overview
Pro stress-test →Quoin Pharmaceuticals is a late-stage specialty pharmaceutical company developing treatments for rare and orphan diseases, with primary focus on severe genetic skin disorders. The company's lead asset, QRX003, is a topical lotion poised to deliver the first FDA-approved treatment for Netherton Syndrome, affecting approximately 1 in 200,000 people worldwide.
Strategic Profile
Pro stress-test →Quoin is strategically positioned for near-term value inflection with QRX003 enrollment expected to complete in 1H 2026 and top-line data anticipated in 2H 2026. The company has secured orphan drug designations in the US, EU, and Japan, and is expanding internationally with distribution agreements and regulatory pathways in multiple regions. Diversified pipeline includes topical rapamycin programs for lymphatic and venous malformations targeting unmet needs with no FDA-approved alternatives.
Competitive Landscape
Pro stress-test →Quoin operates in the rare genetic skin disorder market with minimal direct competition given the absence of approved treatments for Netherton Syndrome and target indications. Competitive positioning is strengthened by proprietary Invisicare topical delivery technology and a diversified pipeline addressing multiple underserved orphan diseases. Competitors in the broader orphan pharma space include firms like Palisade Bio and Kiora Pharmaceuticals.
Industry Context
Quoin Pharmaceuticals, Ltd. operates in Specialty Pharmaceuticals - Rare and Orphan Diseases.
Key facts
Founded: 2018 · Headquarters: Ashburn, Virginia